QTL Biosystems Lightspeed and EMD Biosciences Signal Transduction Interactive Pathways | GenomeWeb

QTL Biosystems has announced four new additions to its Lightspeed fluorescence-based kinase and protease assays: PKC-alpha (diabetes and leukemia screening), Akt-1 (cancer), Src (cancer), and p38-alpha (leukemia and lymphoma). QTL said the homogenous assays, which can be read with most commercially available fluorescence spectrometers and multiwell plate readers, are scalable from 96- to 3,456-well formats, and feature limits of detection in the picomolar range.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.